Posted by & filed under Growth & Valuation, Management Issues, Personal Finance.

Description: The new product should help protect against shortages and offer a lower-cost option, the FDA said

Source: MarketWatch.com

Date: Aug 16, 2018

Link: https://www.marketwatch.com/story/tevas-generic-epipen-approved-in-the-us-with-perfect-timing-2018-08-16

Questions for discussion:

  • Explain the rise in stock price of Teva and fall of Mylan, given no pricing or sales estimates have been released yet for the new product?
  • Do you think competition will actually lower the generic price of the product or will Tevla likely match the current generic price offer to consumers?
  • What would you advise management at both firms?

Leave a Reply

Your email address will not be published.